In mouse models, the FMD synergistically improved the cancer-fighting impact of endocrine therapies, such as tamoxifen and fulvestrant, by significantly lowering systemic levels of IGF-1, insulin, and leptin, and impeding AKT–mTOR signaling pathways through the increased expression of EGR1 and PTEN. The gene discussed is IGF1; the disease is cancer.